A citrullinated antigenic vaccine in treatment of autoimmune arthritis

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：Rheumatoid arthritis(RA)is an inflammatory autoimmune disease triggered by antigenic peptides with environmental and genetic risk factors.It has been shown that antigen-specific targeting could be a promising therapeutical strategy for RA by restoring immune tolerance to self-antigens without compro-mising normal immunity.Citrullination of antigens enhances antigenic properties and induces autoim-mune responses.Here,we showed that citrullinated antigenic(citAg)vaccine ameliorated collagen-induced arthritis with decreased T-helper 1(Th1)and Th17 cells,downregulated proinflammatory cytokines including interlukin-6 and tumor necrosis factor-α,and inhibited antigen recall responses.B cell receptor sequencing further revealed that citAg vaccine could dampen the dysregulated V(D)J recom-bination,restoring the immune repertoire.Taken together,the results demonstrated that citAg vaccine might have a therapeutic effect on RA.

外文关键词：

CitAgCitrullinationCollagen type ⅡTherapeutic vaccineImmune toleranceRheumatoid arthritis

作者：

Xu Jin、Tianya Dong、Qian Wang、Yang Xie、Xiangyu Fang、Chaonan Wei、Shuyan Liu、Xi Zheng、Ping Wang、Danxue Zhu、Lulu Cao、Suwei Dong、Kechi Fang、Chao Zhong、Jing Wang、Fanlei Hu、Zhanguo Li

展开 >

作者单位：

Department of Rheumatology and Immunology,Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis,Beijing 100044,China

Peking-Tsinghua Center for Life Sciences,Peking University,Beijing 100871,China

CAS Key Laboratory of Mental Health,Institute of Psychology,Chinese Academy of Sciences,Beijing 100101,Chi-na

Department of Psychology,University of Chinese Academy of Sciences,Beijing 100049,China

Department of Chemical Biology,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China

Institute of Systems Biomedicine,Department of Immunology,NHC Key Laboratory of Medical Immunology(Peking University),Beijing Key Laboratory of Tumor Systems Biology,Peking University Health Science Center,Beijing 100191,China

State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China

Department of Integration of Chinese and Western Medicine,School of Basic Medical Sciences,Peking University,Beijing 100191,China

展开 >

基金：

Guangdong Basic and Applied Basic Research FoundationNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Key R&D Program of ChinaBeijing Nova ProgramBeijing Nova Program

项目编号：

2020B1515130005823718078217177392374202321410042022YFC3602000Z181100006218044Z211100002121163

出版年：

2024

DOI：

10.1016/j.scib.2024.02.042

科学通报(英文版)

中国科学院

科学通报(英文版)

CSTPCD

ISSN：1001-6538

年,卷(期)：2024.69(18)